Skip to content

Yourgene Health

Sector:
MedTech
Invested in:
Calculus EISs

Yourgene Health previously named Premaitha Heath is a molecular diagnostics company that initially focused on non-invasive prenatal tests for Down’s Syndrome and other genetic disorders.

Yourgene’s core NIPT products comprise a CE-IVD (in vitro diagnostic) marked product, ‘IONA®’, which allows clinical laboratories to establish their own NIPT service; and a lab based test, ‘Sage™’, which is available as a service from Yourgene Laboratory Services in Taipei.

Further to its acquisition of Elucigene last year, Yourgene sells the only commercially available pan- European cystic fibrosis testing kit designed specifically to address the most common mutations found across populations of European origin, as well as test kits to detect the most relevant mutations implicated in an increased risk of developing venous thromboembolism, which results in nearly a million deaths in US and Europe each year.

In March 2020 Yourgene unveiled a contract manufacturing agreement with Novacyt SA for a COVID-19 diagnostic test. Under the deal, Yourgene will use its manufacturing facility in Manchester, UK, to ramp up production of Novacyt’s COVID-19 test.

Rationale

Calculus originally realised that market for pre-natal testing was changing as non-invasive methods displaced established procedures.  Yourgene Health’s IONA test is based on analysis of fetal DNA in the mother’s blood which will allow women to forgo an invasive procedure that can be unpleasant and risky to the fetus (1% miscarriage rate). The company has since proceeded to develop and commercialise a range of other genetic tests.

 

Latest News

Yourgene Genomic Services portfolio expansion

Cytox’s genoSCORETM-LAB test can predict the risk of developing Alzheimer’s disease Yourgene Genomic Services to run the array-based test at Citylabs 1.0 in Manchester Manchester, UK – 11 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Genomic Services (“YGS”) has signed a contract with Cytox Ltd (“Cytox”), a collaborative partner, to … Continued

Calculus makes exits in Genedrive and Yourgene

Realisation in Genedrive achieved an average of 2x return for investors, while Yourgene netted an average of 1.64x return Both companies are listed on AIM, and benefitted from significant growth in the share price during the current pandemic, by refocusing their resources to COVID-19 testing Genedrive is a molecular diagnostics company developing and commercialising a … Continued

Yourgene Health unveils agreement for a COVID-19 diagnostic test

Calculus portfolio company Yourgene Health PLC has unveiled a contract manufacturing agreement with Novacyt SA for a COVID-19 diagnostic test. Under the deal, Yourgene will use its manufacturing facility in Manchester, UK, to ramp up production of Novacyt’s COVID-19 test, with the first batches to be shipped from the Manchester site in the next few … Continued

Thermo Fisher Buys 9% Stake in Yourgene Health

Thermo Fisher Scientific has acquired a 9 percent stake in Calculus portfolio company Yourgene Health by exercising warrants it held in the molecular diagnostics company. Under the terms of the agreement, Yourgene will exclusively promote its noninvasive prenatal testing products on Thermo Fisher’s Ion Torrent next-generation sequencing systems in the Southeast Asia markets for three … Continued

Premaitha Health agrees extension with world leader Thermo Fisher Scientific

Calculus Capital portfolio company Premaitha Health Plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, has announced that it has entered into a further extension of the investment agreement with Thermo Fisher Scientific (“Thermo Fisher”) announced on 14 December 2015 and extended as announced on 23 September 2016, further developing this … Continued

Other MedTech Investments

MIP Discovery

MIP Diagnostics is a novel affinity reagent company. The Company’s proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods

Learn more

Arcis Biotechnology

The Arcis group has a suite of long-lasting and fast-acting products that kill a wide range of micro-organisms and bacteria

Learn more

Browse by sector

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

This site uses cookies as described in our Cookie Policy. By continuing to browse this site you are agreeing to our use of cookies.

I have read and understood this important information

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

This site uses cookies as described in our Cookie Policy. By continuing to browse this site you are agreeing to our use of cookies.

I have read and understood this important information